Nelfinavir Mesylate
Nelfinavir Mesylate is a pharmaceutical drug with 85 clinical trials. Historical success rate of 94.8%.
Success Metrics
Based on 73 completed trials
Phase Distribution
Phase Distribution
20
Early Stage
27
Mid Stage
17
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
93.6%
73 of 78 finished
6.4%
5 ended early
0
trials recruiting
85
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Nelfinavir Mesylate in Treating Patients With Kaposi Sarcoma
Metformin, Nelfinavir, and Bortezomib in Treating Patients With Relapsed and/or Refractory Multiple Myeloma
Chemotherapy, Stereotactic Body Radiation Therapy & Nelfinavir Mesylate in Locally Advanced Pancreatic Cancer
Stereotactic Radiation, Nelfinavir Mesylate & Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Cancer
Paclitaxel in Treating Patients With AIDS-Related Kaposi's Sarcoma
Clinical Trials (85)
Nelfinavir Mesylate in Treating Patients With Kaposi Sarcoma
Metformin, Nelfinavir, and Bortezomib in Treating Patients With Relapsed and/or Refractory Multiple Myeloma
Chemotherapy, Stereotactic Body Radiation Therapy & Nelfinavir Mesylate in Locally Advanced Pancreatic Cancer
Stereotactic Radiation, Nelfinavir Mesylate & Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Cancer
Paclitaxel in Treating Patients With AIDS-Related Kaposi's Sarcoma
Image Guided Hypofractionated Radiation Therapy, Nelfinavir Mesylate, Pembrolizumab, Nivolumab and Atezolizumab in Treating Patients With Advanced Melanoma, Lung, or Kidney Cancer
Safety and Effectiveness of Four Anti-HIV Drug Combinations in HIV-Infected Children and Teens
A Study of Several Anti-HIV Drug Combinations in HIV-Infected Patients Who Have Used Indinavir
Treatment With Combinations of Several Antiviral Drugs in Infants and Young Children With HIV Infection
A Study of the Safety and Effectiveness of Treating Advanced AIDS Patients Between Ages 4 and 22 With 7 Drugs, Some at Higher Than Usual Doses
Drug Interactions of Amprenavir and Efavirenz, in Combination With a Second Protease Inhibitor, in HIV-Negative Volunteers
The Effectiveness of Nelfinavir and Efavirenz, Used Alone or Together, Combined With Other Anti-HIV Drugs in Patients Who Have Taken Anti-HIV Drugs
Combination Treatment With and Without Protease Inhibitors for Women Who Begin Therapy for HIV Infection During Pregnancy
A Study on Amprenavir in Combination With Other Anti-HIV Drugs in HIV-Positive Patients
A Randomized Trial of the Efficacy and Safety of a Strategy of Starting With Nelfinavir Versus Ritonavir Added to Background Antiretroviral (AR) Nucleoside Therapy in HIV-Infected Individuals With CD4+ Cell Counts Less Than or Equal to 200/mm3
A Study on the Effect of Chemotherapy Combined With Anti-HIV Drugs in HIV-Positive Patients
A Study to Learn More About MAC Disease and the Use of Anti-HIV Drugs in Patients With Advanced HIV Infection
A Study of the Effectiveness of Different Anti-HIV Treatments in HIV-Positive Individuals Who Have Been on a Protease Inhibitor-Containing Drug Regimen for at Least 16 Weeks
A Study to Compare Two Different Anti-HIV Drug Regimens
Safety, Tolerability, and Anti-HIV Activity of DMP 266 (Efavirenz) in Combination With Nelfinavir in HIV-Positive Children
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 85